“Trials indicate that a larger percentage of patients than initially thought will benefit from expanded treatment with a stent-retrieval device in the setting of continued obstruction of a large vessel by a blood clot even after tPA is administered,” he said.
Dr. Glatter, who was not involved in the study, also noted that “an estimated 240,000 of the nearly 700,000 ischemic stroke victims in the U.S. are eligible for treatment using clot-retriever technology. However, the data indicates that only about 13,000 procedures were performed in U.S. hospitals over the past year. Based on this, there appears to be an opportunity to potentially treat a greater number of patients.”
Medtronic, which sells the Solitaire system, funded the study. Dr. Goyal and other coauthors have received additional fees from the company.